Novavax, Inc. Overview
Pro stress-test →Novavax is a public biopharmaceutical company specializing in the development and commercialization of recombinant nanoparticle vaccines. The company gained significant prominence through its COVID-19 vaccine (Nuvaxovid) and has expanded its portfolio to include RSV and other respiratory vaccines, positioning itself as a key player in infectious disease prevention.
Strategic Profile
Pro stress-test →Novavax differentiates itself through proprietary recombinant nanoparticle vaccine technology platform, which provides advantages in manufacturing scalability and temperature stability compared to some competitors. The company has secured regulatory approvals globally and is pursuing expansion into additional vaccine markets, including combination vaccines and endemic disease applications.
Competitive Landscape
Pro stress-test →Novavax competes directly with Pfizer/BioNTech, Moderna, Johnson & Johnson, and GSK in the vaccine market. Against Moderna and BioNTech (mRNA vaccines), Novavax's recombinant protein approach offers different manufacturing and stability profiles. Competition is primarily based on efficacy data, regulatory approval timelines, manufacturing capacity, and global distribution networks.
Industry Context
Novavax, Inc. operates in Biopharmaceutical - Vaccines & Immunology.
Key facts
Founded: 1987 · Headquarters: Gaithersburg, Maryland, US